SK Bioscience Rises Two Levels in MSCI ESG Rating

B to BBB... Two-Level Rating Upgrade in One Year

[Asia Economy Reporter Myunghwan Lee] SK Bioscience received a report card showing a two-step improvement compared to the previous evaluation in the environmental, social, and governance (ESG) assessment conducted by a global institution.

SK Bioscience announced on the 3rd that it received a 'BBB' rating in last year's ESG evaluation conducted by Morgan Stanley Capital International (MSCI). This is a two-step increase from the B rating it received in its first evaluation in 2021, achieved within one year.

Since 1999, MSCI has evaluated listed companies worldwide based on 10 themes and 35 key issues in the areas of environment, society, and governance, publishing the results annually. MSCI ESG evaluation results are used as important investment references by major global investment firms.

According to the latest MSCI report, SK Bioscience continuously strengthened the independence of its board of directors in the governance area, enhanced transparency in accounting risk management through systematic audits and information disclosure. In the social area, the company was highly evaluated for its efforts in human resource development.

Going forward, SK Bioscience plans to further strengthen its ESG management activities through regular publication of ESG reports, implementation of climate change response strategies and carbon neutrality roadmaps, conducting human rights impact assessments, and ESG evaluation and management support of its supply chain.

Jae-yong Ahn, CEO of SK Bioscience, said, "Advancing ESG management is now an essential item for all global standard companies," adding, "We will establish ourselves as a true global leading company by pursuing stakeholder happiness and enhancing the business management environment centered on our core mission of promoting global public health."